1. Short title This Act may be cited as the Federal Kratom Consumer Protection Act . 2. Access to kratom (a) Openness in research (1) In general During the period that begins 30 days after the date of enactment of this Act and ends 90 days after such date of enactment, the Secretary, acting through the Commissioner, shall hold at least one hearing that provides an open forum for the discussion on the current scientific data and information about safety and use of products containing kratom or kratom-derived products marketed as a food, dietary ingredient, or dietary supplement. (2) Hearing requirements The hearing under paragraph (1) shall— (A) include input from leading scientific researchers on kratom and kratom-derived products; and (B) consider— (i) how many individuals in the United States consume kratom and kratom-derived products; (ii) the scope, scale, and degree of dependence or addiction associated with kratom, mitragynine, and 7–hydroxymitragynine; (iii) the causality of deaths in which kratom or kratom-derived products are associated, including instances in which— (I) a kratom-containing product or kratom-derived product was consumed together with legal or illegal drugs; or (II) the kratom-containing product or kratom-derived product consumed was contaminated with a different non-drug adulterant known to endanger health; (iv) whether use of kratom or kratom-derived products is directly linked to the use of more dangerous scheduled substances; (v) any adverse health impacts that could be expected if kratom or kratom-derived were no longer available